ATE196140T1 - Substituierte benzylaminoquinuclidine als substanz p antagonisten - Google Patents

Substituierte benzylaminoquinuclidine als substanz p antagonisten

Info

Publication number
ATE196140T1
ATE196140T1 AT93922754T AT93922754T ATE196140T1 AT E196140 T1 ATE196140 T1 AT E196140T1 AT 93922754 T AT93922754 T AT 93922754T AT 93922754 T AT93922754 T AT 93922754T AT E196140 T1 ATE196140 T1 AT E196140T1
Authority
AT
Austria
Prior art keywords
carbon atoms
alkyl
hydrogen
disorders
substituted
Prior art date
Application number
AT93922754T
Other languages
English (en)
Inventor
Fumitaka Ito
Kunio Satake
Kaoru Shimada
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE196140T1 publication Critical patent/ATE196140T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT93922754T 1992-10-21 1993-09-30 Substituierte benzylaminoquinuclidine als substanz p antagonisten ATE196140T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4283135A JP2656699B2 (ja) 1992-10-21 1992-10-21 置換ベンジルアミノキヌクリジン
PCT/US1993/009168 WO1994008997A1 (en) 1992-10-21 1993-09-30 Substituted benzylaminoquinuclidines as substance p antagonists

Publications (1)

Publication Number Publication Date
ATE196140T1 true ATE196140T1 (de) 2000-09-15

Family

ID=17661684

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93922754T ATE196140T1 (de) 1992-10-21 1993-09-30 Substituierte benzylaminoquinuclidine als substanz p antagonisten

Country Status (16)

Country Link
EP (1) EP0665844B1 (de)
JP (1) JP2656699B2 (de)
AT (1) ATE196140T1 (de)
AU (1) AU5165393A (de)
CA (1) CA2146259C (de)
DE (1) DE69329386T2 (de)
DK (1) DK0665844T3 (de)
ES (1) ES2149215T3 (de)
FI (1) FI114636B (de)
GR (1) GR3034498T3 (de)
HU (1) HUT65133A (de)
IL (1) IL107292A0 (de)
MX (1) MX9306527A (de)
PT (1) PT665844E (de)
WO (1) WO1994008997A1 (de)
ZA (1) ZA937780B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014845A1 (en) * 1994-11-10 1996-05-23 Pfizer Inc. Nk-1 receptor antagonists for the treatment of eye disorders
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
DK1246806T3 (da) 1999-11-03 2008-06-16 Amr Technology Inc Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin
MXPA03000275A (es) 2000-07-11 2004-12-13 Albany Molecular Res Inc Nuevas tetrahidroisoquinolinas substituidas con 4-fenilo y su uso terapeutico.
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
UA91341C2 (ru) 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP2413932A4 (de) 2009-04-01 2012-09-19 Merck Sharp & Dohme Hemmer der akt-aktivität
CN102595902B (zh) 2009-05-12 2015-04-29 阿尔巴尼分子研究公司 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー (S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (de) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Neue verbindungen als erk-hemmer
EP3919620A1 (de) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
EP3706742B1 (de) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5-inhibitoren
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
RU2092486C1 (ru) * 1991-05-22 1997-10-10 Пфайзер Инк. Замещенные 3-аминохинуклидины

Also Published As

Publication number Publication date
GR3034498T3 (en) 2000-12-29
HU9302965D0 (en) 1993-12-28
ES2149215T3 (es) 2000-11-01
ZA937780B (en) 1995-04-20
CA2146259A1 (en) 1994-04-28
PT665844E (pt) 2001-01-31
AU5165393A (en) 1994-05-09
HUT65133A (en) 1994-04-28
EP0665844B1 (de) 2000-09-06
DE69329386D1 (de) 2000-10-12
DK0665844T3 (da) 2000-10-16
DE69329386T2 (de) 2001-01-04
JPH06135963A (ja) 1994-05-17
FI114636B (fi) 2004-11-30
EP0665844A1 (de) 1995-08-09
WO1994008997A1 (en) 1994-04-28
IL107292A0 (en) 1994-01-25
FI934626A0 (fi) 1993-10-20
CA2146259C (en) 1998-04-07
FI934626L (fi) 1994-04-22
MX9306527A (es) 1994-07-29
JP2656699B2 (ja) 1997-09-24

Similar Documents

Publication Publication Date Title
DE69329386D1 (de) Substituierte benzylaminoquinuclidine als substanz p antagonisten
DE69923849D1 (de) Quinolin-2-on-derivate verwendbar als antikrebsmittel
DE69331190D1 (de) Überbrückte azabicyclische derivate als substanz p antagonisten
ES534624A0 (es) Un procedimiento para preparar un derivado de 1,8-naftiridina
GB8501192D0 (en) Therapeutic agents
MY104335A (en) 4-aminophridine deravatives
ES2098023T3 (es) Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.
DE69711920D1 (de) Neue histidinderivate, verfahren zu ihrer herstellung und ihre verwendung als mittel gegen freie radikale
DE69918046D1 (de) Neue basische Derivate von Benz(e)isoindol-1-onen und Pyrrolo(3,4-c)chinolin-1-onen mit 5-HT3-antagonistischer Aktivität, ihre Herstellung und ihre therapeutische Verwendung
HU913892D0 (en) Method for producing new alkyl-amino-alkyl-amine and -ether derivatives and pharmaceutical preparatives containing said compounds
SE7502243L (de)
EP0626369A4 (de) Benzolsulfonamid derivate.
MX9702089A (es) Carboxamidas biciclicas como antagonistas de 5-ht1a.
ATE247662T1 (de) Indolocarbazolalkaloide aus einer marinen actinomycete
ES2023760A6 (es) Procedimiento para la preparacion de derivados benzotiazinicos.
IS5623A (is) Ný efnasambönd
TW353071B (en) Chromene compounds with neutroleptic activity, their preparation and pharmaceutical compositions
FR2695643B1 (fr) Dérivés d'uréido-acétamide, leur préparation et les médicaments les contenant.
ES8602825A1 (es) Un procedimiento para preparar un compuesto fosforoditioico

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee